home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407f.zip
/
M9471080.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
2KB
|
32 lines
Document 1080
DOCN M9471080
TI Cost-benefit analysis of bone marrow (BM) immunophenotyping (IP) in the
staging of non-Hodgkin's lymphoma (NHL) (Meeting abstract).
DT 9409
AU Denes AE; Hathaway C; St. John's Mercy Medical Center, St. Louis, MO
63141
SO Proc Annu Meet Am Soc Clin Oncol; 13:A1332 1994. Unique Identifier :
AIDSLINE ICDB/94601328
AB BM IP is often used in conjunction with light microscopy (LM) in the
staging evaluation of patients (pts) with NHL. We conducted a
retrospective review of 50 BM staging procedures to determine the
sensitivity of IP in the detection of occult BM involvement in pts with
NHL. IP was performed on an Epics II Profile flow cytometer (Coulter)
using a panel of 6-15 antibodies (n=10). Pts ranged in age from 20-86 yr
and the male:female ratio was 23:27. Results are summarized in a table.
In only one pt was a clonal proliferation detected by IP that was not
apparent by LM. This was a B cell lymphoproliferative disorder in an
HIV+ pt with fever and diffuse adenopathy. The total cost of IP in these
50 pts was 49,824 dollars (range 576-1344 dollars, m=996 dollars/pt
sample). These results indicate that IP is not more sensitive than LM in
the detection of BM involvement by NHL. The routine use of BM IP in the
staging evaluation of pts with NHL is not recommended.
DE Adult Aged Aged, 80 and over Bone Marrow/*PATHOLOGY Cost-Benefit
Analysis Female Human Immunophenotyping/*ECONOMICS Lymphoma,
Non-Hodgkin's/ECONOMICS/*PATHOLOGY Male Middle Age Neoplasm Staging
Retrospective Studies MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).